Literature DB >> 23575324

Tuberculosis patients in primary care do not start treatment. What role do health system delays play?

M M Claassens1, E du Toit, R Dunbar, C Lombard, D A Enarson, N Beyers, M W Borgdorff.   

Abstract

SETTING: Primary health care facilities in five provinces of South Africa.
OBJECTIVE: To investigate the association between the proportion of sputum results with a prolonged smear turnaround time and the proportion of smear-positive tuberculosis (TB) cases initially lost to follow-up.
DESIGN: The unit of investigation was a primary health care facility and the outcome was the initial loss to follow-up rate per facility, which was calculated by comparing the sputum register with the TB treatment register. A prolonged turnaround time was defined as more than 48 h from when the sputum sample was documented in the sputum register to receipt of the result at the facility.
RESULTS: The mean initial loss to follow-up rate was 25% (95%CI 22-28). Smear turnaround time overall was inversely associated with initial loss to follow-up (P = 0.008), when comparing Category 2 (33-66% turnaround time within 48 h) with Category 1 (0-32%) (OR 0.73, 95%CI 0.48-1.13, P = 0.163) and when comparing Category 3 (67-100%) with Category 1 (OR 0.62, 95%CI 0.39-0.99, P = 0.045). The population preventable fraction of initial loss to follow-up (when turnaround time was <48 h in ≥67% of smear results) was 21%.
CONCLUSION: Initial loss to follow-up should be reported as part of the TB programme to ensure that patients are initiated on treatment to prevent transmission within communities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23575324     DOI: 10.5588/ijtld.12.0505

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  26 in total

1.  Pre-treatment loss to follow-up among smear-positive TB patients in tertiary hospitals, Quetta, Pakistan.

Authors:  A Wali; A M V Kumar; S G Hinderaker; E Heldal; E Qadeer; R Fatima; A Ullah; N Safdar; A Yaqoob; K Anwar; M Ul Haq
Journal:  Public Health Action       Date:  2017-03-21

2.  Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.

Authors:  Krishna P Reddy; C Robert Horsburgh; Robin Wood; Naomi F Fields; Michael P Girouard; Sydney Costantini; Taige Hou; Kenneth A Freedberg; Rochelle P Walensky
Journal:  Ann Am Thorac Soc       Date:  2020-02

Review 3.  Defining the needs for next generation assays for tuberculosis.

Authors:  Claudia M Denkinger; Sandra V Kik; Daniela Maria Cirillo; Martina Casenghi; Thomas Shinnick; Karin Weyer; Chris Gilpin; Catharina C Boehme; Marco Schito; Michael Kimerling; Madhukar Pai
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

Review 4.  Target product profile of a molecular drug-susceptibility test for use in microscopy centers.

Authors:  Claudia M Denkinger; David Dolinger; Marco Schito; William Wells; Frank Cobelens; Madhukar Pai; Matteo Zignol; Daniela Maria Cirillo; David Alland; Martina Casenghi; Jim Gallarda; Catharina C Boehme; Mark D Perkins
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

5.  Pre-treatment lost to follow-up tuberculosis patients, Chongwe, Zambia, 2017: a retrospective cohort study.

Authors:  M Chilembo; S Oguri; Y Matsuoka; M Ota; P Musiankuni; J Kabungo
Journal:  Public Health Action       Date:  2020-03-21

6.  Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa.

Authors:  Nomonde R Dlamini-Mvelase; Lise Werner; Rogerio Phili; Lindiwe P Cele; Koleka P Mlisana
Journal:  BMC Infect Dis       Date:  2014-08-16       Impact factor: 3.090

7.  Seasonality and Trend Forecasting of Tuberculosis Prevalence Data in Eastern Cape, South Africa, Using a Hybrid Model.

Authors:  Adeboye Azeez; Davies Obaromi; Akinwumi Odeyemi; James Ndege; Ruffin Muntabayi
Journal:  Int J Environ Res Public Health       Date:  2016-07-26       Impact factor: 3.390

8.  It's complicated: why do tuberculosis patients not initiate or stay adherent to treatment? A qualitative study from South Africa.

Authors:  Donald Skinner; Mareli Claassens
Journal:  BMC Infect Dis       Date:  2016-11-25       Impact factor: 3.090

9.  Microbiologically Confirmed Tuberculosis: Factors Associated with Pre-Treatment Loss to Follow-Up, and Time to Treatment Initiation.

Authors:  Judith Mwansa-Kambafwile; Boitumelo Maitshotlo; Andrew Black
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

10.  The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.

Authors:  Pren Naidoo; Grant Theron; Molebogeng X Rangaka; Violet N Chihota; Louise Vaughan; Zameer O Brey; Yogan Pillay
Journal:  J Infect Dis       Date:  2017-11-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.